

About Paul B. Beeson, MD (1908-2006)

Dr. Paul B. Beeson, a renowned physician, researcher, and teacher, was the inspiration behind the creation of the Paul B. Beeson Career Development Awards in Aging Research Program. It was his vision to increase the number of physicians with a combined clinical, academic, and scientific expertise to care for a growing older population.

At the time of his death, Dr. Beeson was professor emeritus of medicine at the University of Washington. Although "retired," he remained active in the field of aging research, attending meetings and advising many Beeson Scholars. In his long and distinguished career, he profoundly influenced the career paths of many physician-scientists and was stalwart in his concern for the care and dignity of patients.

To date, 210 scholars supported by the Beeson Program have become leaders in geriatric medicine and aging research throughout the United States and the Island of Ireland. The careers of these remarkable Scholars serve as a lasting testament to Dr. Beeson's enduring legacy as they seek to provide the best possible care for older adults and train the next generation of leaders in aging research and geriatrics.

2015 Program Advisory Committee

Thomas Gill, MD, Chair Yale University School of Medicine

Liana G. Apostolova, MD, MSc Indiana University School of Medicine

Kenneth Covinsky, MD, MPH University of California, San Francisco School of Medicine


E. Wesley Ely, MD, MPH, FCCP Vanderbilt University School of Medicine/VA-GRECC

Jean Kutner, MD, MSPH University of Colorado Anschutz Medical Campus

Mark Lachs, MD Weill Cornell Medicine

Alison A. Moore, MD, MPHDavid Geffen School of Medicine at the University of California, Los Angeles

Raymond L. Yung, MB, ChB University of Michigan Medical School



Letter from Thomas Gill, MD

Chair of the Program Advisory Committee

When the Beeson Program was launched in 1994, this new training vehicle focused exclusively on physician investigators. With the added support from the National Institute on Aging in 2004, the program dramatically expanded in both size and scope and began to include additional disciplines. That expansion was a key development—one that greatly strengthened the program by embedding it within multiple fields beyond medicine and by enabling years of fruitful, multidisciplinary collaborations.

Across the Atlantic, the 2007 expansion of the Beeson Program into the Republic of Ireland and Northern Ireland gave rise to another remarkable group of leaders in aging research. More recently, many of our scholars have taken advantage of the Beeson Scholars/Change AGEnts Action Fund, generously supported by the John A. Hartford Foundation. Some scholars are moving into policy realms that they may not have otherwise considered, while others are translating their research into efforts aimed at transforming patient care on a local and national level.

Many new ideas and partnerships have blossomed at our annual Beeson meetings, where we showcase the unique and important contributions of scholars from many disciplines in advancing the care and management of older patients.

We're delighted to introduce the 2013 Beeson Scholars, whose impressive accomplishments add significantly to this rich body of research talent. Remarkably, with an emergency medicine physician, geriatrician, neurologist, cardiologist, neuropsychologist, neuroradiologist, and nurse, no discipline is represented more than once. That extraordinary diversity not only reflects our increasingly broad pool of applicants but also provides a durable platform from which to expand our reach even further in broadening and deepening the knowledge base in aging research. In the Beeson Program, success builds success.

We're entering an era in which the opportunities for scientific discovery have never been greater. But we're also working in an environment where the resources needed to support that research are often in short supply. We're proud of the success of our Beeson scholars and graduates in competing for these precious resources, in acquiring new skills and in identifying the best opportunities to advance their own diverse disciplines.

Through their continued growth, inspiration, and collaboration, we're all enriched.

Thomas Gill, MD

Thomas MDill





Program Overview

Over the past two decades, the Paul B. Beeson Career Development Awards in Aging Research Program has recognized 200 investigators as Beeson Scholars. Collectively, our awardees' research covers a wide range of aging-related topics in basic, clinical, behavioral, social, epidemiological, and health services sciences.

In 2004, the program's funders established a strategic public-private partnership to address the evolving challenges of biomedical research in the 21st century. An alliance forged by the National Institute on Aging (NIA), The John A. Hartford Foundation, Atlantic Philanthropies, The Starr Foundation, and AFAR began jointly funding and administering the Beeson Program. This dynamic partnership has greatly strengthened the Program in multiple ways.

For example, the Program benefits from the rigorous peer-review process of the National Institutes of Health (NIH), and the Program's inclusion in the NIH system has also raised awareness and attracted a more diverse pool of applicants. Combined public-private support, meanwhile, has enabled the Program to offer larger awards and draw top candidates. And thanks to the continued private support which has greater financial flexibility, the Program can sustain its unique networking and mentoring aspects.

The partnership supports other initiatives as well, such as an annual meeting for Beeson Scholars and alumni, field-building activities in aging policy and advocacy, and efforts to raise the profile of aging research in other areas of medicine.

This joint venture has paid off handsomely. More than half of the Scholars now hold leadership positions ranging from Center Director, Department Chair, Division Chief to Director of Fellowship Program. Many have received the coveted R01 research award, which bestows upon its recipients a considerable level of prestige as independent investigators. Those numbers will certainly rise as the Scholars in the most recent cohorts advance further along their career trajectories. The Beeson Program has proven critical to developing their careers and establishing them in the field of aging research. Together, these results have strengthened our conviction that the Beeson Program remains an unqualified success, providing vital financial, networking, and mentoring support to physician-scientists at a decisive juncture in their careers.

The Multiplier Effect

In 2014, the Beeson Outreach Fund became the Beeson Scholars/Change AGEnts Action Fund, which supports projects by Beeson Scholars that align with the new Hartford Change AGEnts Initiative. The ambitious effort, with funding from the John A. Hartford Foundation, focuses on inter-professional collaboration and promoting change in how healthcare is delivered to older adults.

"Collaboration has been a hallmark of AFAR's work and the Beeson Scholars program since its inception, and the recent partnership between the Beeson program and the Hartford Change AGEnts initiative has been especially meaningful to the Foundation as it perfectly embodies our strategies and vision for the future," says Marcus R. Escobedo, Senior Program Officer at the John A. Hartford Foundation.

"While our legacy programs like the Beeson award have been developing experts in aging research and academia, our new initiatives such as the Change AGEnts seek to support and connect those experts so they can take their knowledge into health care delivery settings to create change in practice," he says. "The Beeson/Change AGEnts Action Fund not only has supported innovative and collaborative practice change projects, but also it serves to encourage other Beeson Scholars to take their place in the Change AGEnts movement, and we couldn't be more pleased."

In other news, with funding from the Beeson Ireland Program, AFAR has partnered with the Center for Ageing Research and Development in Ireland (CARDI), to jointly support two research fellows in Ireland.

Finally, through grant extensions the annual meetings will be supported through 2018, ensuring that scholars and alumni will have continued access to this unique venue for mentorship and collaboration. The National Institute on Aging, has been a key co-sponsor and administrator of the program for more than a decade.

Chyren Hunter, PhD, Deputy Director and Training Officer in NIA's Division of Extramural Activities, hails the Beeson award as an important vehicle for the shared vision of AFAR, the NIA, the Hartford Foundation and other sponsors in promoting the careers of researchers with a primary interest in questions about aging and growing older. "Since 2004, the NIA and AFAR have independently but jointly supported a stellar cadre of physicians and other clinically-trained individuals pursuing independent careers in basic, translational and clinical research in aging and geriatrics," Dr. Hunter says. "We are delighted at the success that the Beeson Scholars enjoy and are proud that Beeson scholars are leaders in their respective fields. Their accomplishments do much to help address the growing challenges of our aging society."

Here are some highlights of recent Beeson Scholar-led projects supported by the fund:

Daniel Matlock, MD, MPH (2011) and Daniel Kramer, MD, MPH (2013), joined forces to cohost a symposium on using implantable cardioverter-defibrillators in older adults. The event brought together experts in heart failure, geriatric palliative care, ethics and electrophysiology and generated multiple research ideas that could form the basis for new collaborations. The multidisciplinary group recently published a paper summarizing the ICD Use in Older Adults symposium in the journal Circulation—Cardiovascular Quality and Outcomes, to help identify critical clinical and research problems and suggest a roadmap for improvement.

Alexander Smith, MD, MPH (2012), received funding to support the creation of a series of teaching videos for the *ePrognosis* website and the *ePrognosis*: Cancer Screening smartphone app. *ePrognosis* provides a repository of published geriatric prognostic indices for clinicians to obtain evidence-based information on their patients' prognosis, while the app can guide conversations with older patients on whether to start, stop, or continue breast cancer and/or colorectal cancer screening.

Liana Apostolova (2005) and Jason Karlawish (2000) are working closely to assemble a multidisciplinary group of experts in order to 1) create recommendations for how to communicate a diagnosis of mild cognitive impairment, or MCI, and 2) assess whether and how the recommendations should change when clinicians use an imaging method called amyloid PET to detect evidence of MCI. The group hopes to spur additional discussion and research in the field to improve upon the clinical care of persons with MCI.

May Reed, MD, FACP (1996) and an interdisciplinary team will use established electronic medical record systems to improve the drug prescription process in emergency departments. The project will help providers improve their drug selection and be more judicious in the use of selected medications such as analgesics, anti-emetics, sedatives, hypnotics, and anti-psychotics for older patients in emergency departments.

Letter from Richard Besdine, MD AFAR Medical Officer

The Beeson program came into existence after a series of Institute of Medicine reports that, beginning in 1978, highlighted a growing need for physicians trained in geriatrics and aging research. After the 1993 report called for more support of geriatrics research and training, a group of foundations and nonprofit organizations came together to create the Paul B. Beeson Physician Faculty Scholars in Aging Research Program, now known as the Paul B. Beeson Career Development Awards in Aging Research Program. These funders sought to play a catalytic role by making strategic investments in individuals and organizations positioned to advance research and training that ultimately would result in better care for older Americans. And they succeeded in doing all that and more.

Now, 21 years later, more than 200 clinically-trained investigators proudly can call themselves Beeson Scholars, contributing to advances in nearly every area of aging-related science, and making a real difference in the lives of older adults.

The Beeson Scholar designation is career changing, and solidly establishes Scholars in their area of aging research in their home institutions. Key features that make the Beeson brand so precious include flexible and generous funding, an outstanding support system of Beeson mentors and alumni, and extensive networking opportunities. Scholars are selected from leading medical schools and research institutions across the country.

I proudly introduce the 2013 Scholars, and am confident that they too will be maturing into the leadership role so critically needed for advancing the knowledge, treatment and care of millions of older adults.

Richard W. Besdine, MD

Till (ledo



Marian "Emmy" Betz, MD, MPH

Assistant Professor of Emergency Medicine, University of Colorado School of Medicine

Mentor: Robert Schwartz, MD

Physician Screening of Older Drivers:
Decision Rules for Geriatric Injury Prevention



The ability to drive has long been associated with freedom. "We know from a lot of studies that driving is important to older adults because it helps them stay mobile and independent," says Marian "Emmy" Betz, MD, MPH. "People who stop driving too soon can become depressed and even die early." On the other hand, many common conditions and medications can reduce the ability of seniors to drive safely.

"The problem is that there is no single diagnosis or no single age when suddenly someone is unfit to drive," she says. Also, older adults are unlikely to bring up the topic unless they are already having significant difficulties.

Dr. Betz hopes to make such conversations easier and more useful by developing a screening tool that would let doctors briefly and routinely evaluate the driving capacity of older individuals. Those identified in need of a driving evaluation could be referred to a specialist and receive additional counseling and other resources.

"We need to recognize there comes a time when most people need to stop driving and we need to support older adults so that they can stay active, independent and healthy," Dr. Betz says. "There is life after you hang up the keys."

For her Beeson project, she is validating a screening tool dubbed CRASH, an acronym based on five questions:

- C is for confusion:
 Do you ever feel confused when you're driving?
- R is about driving regularly:
 Are you driving regularly and drive long distances?
- A refers to avoidance:
 Are you avoiding driving alone?
- **S** stands for **seeing**:

 Do you have any difficulty seeing while driving?
- H references handing over:
 Has anyone asked you to hand over the car keys?

Although the questionnaire won't identify everyone in need of more testing, Dr. Betz hopes it will provide the basis for a practical, rapid, and regular screening process. She and her colleagues also are soliciting feedback from older drivers, healthcare providers, and driving specialists. The goal is to combine the screening tool and additional input "to build a program that makes sense and might be feasible instead of just saying to doctors, 'Here's one more thing you should do.' That's not very useful, "she says. If her system works as expected, it also may offer a template for other feasible, acceptable, and effective injury prevention plans.

Her study is recruiting 200 older drivers from primary care clinics; as part of the assessment, Dr. Betz and her team are asking additional questions to predict which of the drivers might score lower on a subsequent one-hour road evaluation. At the same time, the researchers have helped normalize such conservations by embedding questions about driving status into the routine clinical template used by primary care providers.

As an emergency physician, Dr. Betz has a strong interest in injury prevention. "For teen drivers," she says, "research-based policies such as graduated licensing have helped save lives." She began to wonder whether similar research could be translated into improving safety at the other end of the age spectrum. That angle, in turn, helped expand her interest in geriatric emergency medicine into aiding other difficult but necessary discussions of injury prevention among older adults, such as suicide prevention.

The Beeson award "is phenomenal because it's given me the space that I really need to develop, and my productivity has exploded over the past two years." The award also has helped Dr. Betz become active in women's leadership training programs and in mentoring junior women researchers in academic medicine. Unlike other career development awards, Dr. Betz notes, the Beeson Program promotes networking opportunities with both senior leaders and peers in the field. "Really seeing what someone else is doing, encourages you to think big."



Constance Fung, MD, MSHS

Assistant Professor of Medicine, David Geffen School of Medicine at the University of California, Los Angeles

Mentor: Cathy Alessi, MD

Improving Older Adults' Decision Making for Obstructive Sleep Apnea Treatment

In severe cases of obstructive sleep apnea, the throat muscles of a sleeping patient may relax and block the airway 30 times an hour; in extreme cases, the frequency of these obstructions can soar to as many as 120 per hour.

The sleep disorder, if left untreated, can contribute to serious health problems ranging from car crashes caused by sleepy drivers to an increased risk for stroke and heart arrhythmias. Constance Fung, MD, MSHS, estimates that roughly one fifth of older adults have sleep apnea. Far fewer have had it properly treated, much less diagnosed.

Doctors have developed three main strategies to keep the airway open: a snug-fitting mask that delivers continuous positive airway pressure (commonly called CPAP), a mouthpiece or oral device that keeps the throat clear, and surgery that removes tissue from the back and top of the throat. For her Beeson research, Dr. Fung is focusing on the barriers that prevent older adults from accepting or sticking to a treatment plan that could significantly decrease their symptoms.

Eventually, the work could shape a new intervention that more fully engages each patient in the treatment decision. Crucially, the decision aid could help older patients—especially those dealing with other medical conditions—communicate their goals, values and concerns. She notes: "Are they looking more for optimizing quality of life versus extending how long they're living?"

In Phase I, Dr. Fung is exploring the range of factors that influence the decision-making process in older adults. Beyond considerations such as whether a treatment seems unnecessary, unaffordable or uncomfortable, she is focusing on factors such as whether patients can learn and remember how to use the treatment and adjust the settings.

From focus groups, Dr. Fung and colleagues also found significant variability in how much providers were telling older sleep apnea patients about the disorder and its treatment options. "Most of the patients want to know about their disease," she says. "They want to know not just what's first line or what the most obvious choice is but they want to know what the alternatives are."

That information can be critical, as multiple patients have revealed that they had never known about alternatives to CPAP. When that initial therapy proved unworkable for some, Dr. Fung says, "they never came back to see a doctor because they sort of figured there was nothing else to do."

For Phase II of the project, Dr. Fung and her team are using the collected data and additional input from both patients and providers to craft a decision aid specifically for older adults. "We'll recruit patients and show them versions of the prototype and then we'll make changes and try to make it better," Dr. Fung says.

The Beeson award has been invaluable by giving her the protected time to pursue her research aims and career development activities, she says. Already, she has attended training courses and seminars to learn more about health coaching, decision-making, choice analysis, and constructing a good decision aid. Dr. Fung says the support from her multidisciplinary mentoring team and the networking opportunities at the annual Beeson meetings also have been critical to her success.


She has always been interested in how people make decisions. During successive fellowships in geriatrics and sleep medicine, Dr. Fung cared for many older patients who didn't adhere to their prescribed therapy after being diagnosed with obstructive sleep apnea. She then wondered: How could she optimize their treatment plans? Her current research focus is now giving her the best of both worlds: "I'm marrying my interests in decision-making with my interests in improving sleep in older adults."

William Hu, MD, PhD

Assistant Professor of Neurology, Emory University School of Medicine

Mentor: Allan Levey, MD, PhD

Early Cerebrospinal Fluid Detection of Frontotemporal Lobar Degeneration



"From imaging studies, we think that different circuits in the brain are affected," says William Hu, MD, PhD. Researchers have further subdivided frontotemporal lobar degeneration into two main subgroups: one associated with an abnormal protein called TDP-43, and the other linked to an abnormal protein known as tau. Frustratingly, clinicians normally cannot distinguish between these subtypes until they visually inspect the brain after an autopsy, complicating efforts to diagnose patients or enroll them in clinical trials when there is still an opportunity to intervene.

"If we have a drug and we can't identify the right patients, then we can't really do an effective trial. Even if we do, we will have to grossly overpower it to account for people who don't have the right disease," Dr. Hu says. "If clinicians can't predict which patient has what subtype, how would they even figure out which drug to test?"

During his residency, Dr. Hu started looking for any behavioral features that might predict the underlying frontotemporal lobar degeneration subtype. "And really, there weren't any," he says. "It was a frustrating project, but it got me interested in this field." He has since focused on identifying molecular markers that could help clinicians confirm the diagnosis beyond subjective clinical phenomenology. "Because we're talking about behavior changes in the context of life-long behaviors, sometimes it can be tricky to know whether someone is developing abnormal behaviors or just becoming more eccentric as one ages."

So far, he has discovered that a reduction in the ratio between two specific proteins within the cerebrospinal fluid is highly predictive of the TDP-43 disease subtype; three other research groups have since replicated the



finding. "It's very exciting and encouraging that this may potentially become a clinically useful test," Dr. Hu says, noting that the same test might prove useful for amyotrophic lateral sclerosis, also known as Lou Gehrig's disease or ALS.

For a biomarker-based test to be useful, however, clinicians need to have further options when the test result isn't clearly positive or negative. "It's the indeterminate calls that frustrate clinicians, scientists, and patients," Dr. Hu says. "If there are many indeterminate calls, then we're back to the problem of not being able to accurately diagnose patients."

Although Dr. Hu was first drawn to mathematics, he decided that his passion lay more in using the discipline to solve biochemical and molecular problems. For his Beeson research, he is making good use of this background by classifying test results with a data analysis method called machine-based learning. The method uses multiple lines of data—such as age, gender, genetic profile and age of disease onset—to build a model which yields a probability that a patient has one disease subtype or the other. With a more reliable method for classifying patients, clinicians can more easily recruit them for the proper clinical trials and potentially optimize the applicability of candidate drugs.

"In the ever-changing environment of academic medicine, the Beeson award provides a robust mechanism to guarantee me the time and effort to not only pursue my research interests—including my Beeson project—but also additional training," Dr. Hu says. He has already completed courses on biomarkers and machine-based learning that he would not otherwise have had the opportunity to take.

He also values the leadership training, camaraderie, collaboration and mentorship at the Beeson meetings. "I'm really appreciative of the question and answer period during which some of the more senior Beeson awardees and faculty provide on-the-spot mentoring for common questions and concerns. The award provides the protection and the leadership training that are crucial for my success in these activities."



Assistant Professor of Medicine, Harvard Medical School, Assistant Scientist, Hebrew SeniorLife Institute for Aging Research

Mentor: Susan Mitchell, MD, MPH

Patient-Centered Outcomes of Implantable Defibrillator Therapy in Older Patients

Every year, doctors place more than 50,000 devices known as implantable cardioverter-defibrillators (ICDs) in patients aged 65 and older. These patients have experienced a life-threatening disturbance of the heart's rhythm—a condition known as arrhythmia—or are at risk of developing one due to a prior heart attack, heart failure, or reduced muscle function from another cause.

Daniel Kramer, MD, MPH, has long appreciated the device's "extraordinary" ability to monitor the heart's rhythm, detect the emergence and persistence of a dangerous arrhythmia, and then deliver a shock to reset the beat and save a patient's life. Less understood, however, is the quality of life of older patients with ICDs.

"Older people are particularly sensitive to questions around whether they will live not just longer, but will they be independent, or will they be functional," Dr. Kramer notes. In other words, will their quality of life be high enough to make its prolongation desirable given the device's side effects? "And then for older patients, even if the defibrillator does extend their lives, eventually they will have to confront some end-of-life care issues," such as wanting the device turned off as they near death.

Through his Beeson project, Dr. Kramer hopes to gain a clearer understanding of patients' experience living with ICDs, and then use that information to help improve their quality of life. He is delving into large databases of those who have received ICDs to examine how long they live afterward, where they live—such as a nursing home, hospice, or their own home—and how well they function.

Through a small pilot study of older and sicker patients implanted with defibrillators at Boston's Beth Israel Deaconess Medical Center, Dr. Kramer hopes to better understand their goals, decisions, discussions with providers, and end-of-life experiences. Eventually, his research could aid the decision-making process by expanding quality of life descriptions along with survival rates and potential complications. "Telling somebody that they'll be alive in a year is not the same as telling them that they'll be alive and independent," he says.

"We might be able to improve or add a little more depth to the kinds of discussions that we would like patients to have before they elect to get an ICD." In addition, the research might identify patients at higher risk of requiring nursing home or hospice care after receiving the devices, giving doctors a better chance to ward off preventable transfers or initiate end-of-life discussions.

Dr. Kramer first became interested in heart rhythm cardiology and ICDs as a medical student: "I was really struck very early on in my training about the power of these particular devices," he says, noting that he also has a personal connection to his research specialty. "I have had a few family members die suddenly from cardio-vascular disease. It's not uncommon for me to think about that when I'm taking care of these patients or putting in these devices myself."

The Beeson award has provided critical support for his research: "It's a career development award like no other. It comes with the funding and the networking and the resources that I think otherwise would make this kind of science very difficult." As a sub-specialist, he also has benefited enormously from networking with other researchers at the annual meetings and receiving career development advice. "I'm trained as a cardiac electrophysiologist; I'm not a geriatrician," he says. "so I have learned a lot from working with and hearing from other people in the program who have exclusively focused on the needs of older patients."

From his ongoing research and discussions, Dr. Kramer has broadened his focus to glean even more information from ICDs. "I think there are a lot of opportunities just using some of the data sources that I'm pulling from to more clearly characterize the experience of living with these devices as the underlying disease progresses," he says. The devices themselves capture critical data that could more clearly illuminate each patient's functional status and disease trajectory. Together, the information could play a major role in shaping interventions that improve outcomes, enhance quality of life and inform critical end-of-life decisions

Ozioma Okonkwo, PhD

Assistant Professor of Medicine, University of Wisconsin School of Medicine and Public Health

Mentor: Sterling Johnson, PhD

Early detection of asymptomatic middle-age adults at risk for Alzheimer's disease

By 2025, an estimated 7.1 million Americans aged 65 and over will have Alzheimer's disease—a remarkable increase of 40 percent from current levels. Warding off a public health crisis may well depend on detecting the disease while it is still asymptomatic and potentially treatable with experimental therapies.

"The field is beginning to appreciate that therapeutic agents are more likely to be effective if they are administered at the earliest stages of the disease, before the individual has experienced irreversible neuronal loss and related brain lesions," says Ozioma Okonkwo, PhD. "But in order to administer or implement the interventions at such an early stage, you have to be able to identify the individuals who are at that stage."

A recent revision of the diagnostic criteria for Alzheimer's formally recognizes pre-clinical Alzheimer's as the earliest stage of disease progression. At this point, individuals are still cognitively normal but beginning to accumulate the pathological signs of disease that will eventually lead to dementia. To identify this early stage, doctors must do an invasive lumbar puncture to look for changes in the cerebrospinal fluid or conduct an expensive PET imaging scan to identify specific biomarkers of disease in the brain.

One goal of Dr. Okonkwo's Beeson project is to identify a diagnostic method that is less expensive, less invasive, and more widely available while still accurately reflecting this preclinical stage. He is tapping the Wisconsin Registry for Alzheimer's Prevention, a group of more than 1,500 middle-aged adults who are asymptomatic but at increased risk of Alzheimer's because they have one or two parents with the disease. The study participants have undergone cognitive and clinical assessments over time, including MRI-based imaging. Some also have had PET scans and lumbar punctures.

By combining the available PET, CSF, and cognitive data, Dr. Okonkwo aims to identify those individuals in Stage 3 preclinical Alzheimer's, the last stop before they shift into a more clinically apparent stage marked by mild cognitive impairment. For a control group, he hopes to identify patients at Stage 0, who lack any signs of neuronal dysfunction or cognitive impairment. For both sets

of patients, he will then use cheaper and non-invasive MRI-based scans to image the brain over time: one type of MRI measures brain structure and a second assesses its perfusion. Dr. Okonkwo can then apply a sophisticated statistical tool to model the pattern of structure-perfusion changes in the brain that typify Stage 3 preclinical Alzheimer's. This can then be summarized into a risk score that will be tested against core Alzheimer biomarkers such as β -amyloid.

If validated, this risk score could be used to discern whether other asymptomatic patients, who have only undergone MRI imaging but not PET scanning or lumbar puncture, are at increased risk for Alzheimer's as a result of harboring the same pathological changes seen in Stage 3 preclinical Alzheimer's. After identifying this telltale pattern and at-risk individuals, Dr. Okonkwo says other differences are likely to emerge: some patients may progress quickly to clinically apparent Alzheimer's, while others barely change. "What is it that some individuals remain resilient to the otherwise expected effects of the brain disease?" he asks.

That question lies at the heart of his research and its unifying theme of how to promote successful aging. For example, he says, "Two people could arrive at the same clinical diagnosis via slightly different pathways." Understanding that distinction could be crucial when trying to determine which therapy to use.

Dr. Okonkwo has long been curious about the brain and cognition. "I started to think that I would like to study these things not just in theory but in human beings."

The Beeson award and the annual meeting "have helped me get in touch with my peers in the field who are doing very exciting work that complements and even help expand my work," he says. From talking with another Beeson Scholar during the annual meeting in 2014, for example, "we found out that we were both interested in this notion of resilience to aging and disease." The two scholars have since submitted an NIH grant proposal to explore the genetic basis of resilience. "It is this type of connection that the Beeson program helps to establish and sustain."



Janey C. Peterson, EdD, MS, RN

Associate Professor of Clinical Epidemiology in Medicine, Weill Cornell Medicine

Mentor: Mark Lachs, MD

INSPIRE: Intervention to Support Participation in Regular Exercise in the Elderly

As the United States population ages, more people are living longer with chronic illnesses which also means that they are at higher risk of becoming disabled. Physical activity can stave off disability and even improve the functional status of older adults who have already begun to face illness-related complications.

"There's a window of opportunity where we can help people to maintain or improve their function through increasing physical activity, but health providers prescribe exercise to only about a third of older adults," says Janey Peterson, EdD, MS, RN. The U.S. Surgeon General, by contrast, has recommended that adults should get at least 150 minutes of moderate-intensity exercise every week. Those guidelines, however, can be overwhelming to older individuals with multiple serious chronic diseases such as a history of congestive heart failure, diabetes or myocardial infarction.

Dr. Peterson hopes to find the right balance with recommendations that are both effective and reasonable for older, high-risk patients living with combinations of high-risk chronic conditions. Her early data suggest that even low levels of physical activity for this largely sedentary group can have a very meaningful impact on extending life and decreasing the risk of major morbidity and mortality. To help motivate her patients, Dr. Peterson has developed an intervention that induces Positive Affect—a feeling of happiness or wellbeing. Positive Affect, she explains, can lead to greater confidence and motivation and promote more flexible thinking and healthier behaviors. "That's really the secret sauce to long-term behavior change," she says.

Her research team adapted the intervention, initially developed and tested on healthy young adults on college campuses, and translated it to older clinical populations with chronic disease. "We ask people, 'What are some small things in your life that make you smile, that make you feel good?'" Then, we send them surprise gifts, like a picture frame for a photo of loved ones, to help strengthen the induction of positive affect. The researchers also ask the patients to identify core values and life priorities that are important to them, a second construct which is

called Self-Affirmation. "Combining Positive Affect and Self-Affirmation is an important motivator for people, because it enables them to connect behavior change to things that are important in their life."

In a previous, randomized controlled trial of patients recovering from coronary angioplasty, she says, "we had phenomenal results." Compared to patients who were given only educational materials, people who received the Positive Affect intervention were 1.7 times more likely to achieve their one-year exercise goal: engaging in physical activity the equivalent of walking just over 4 miles/week. The Positive Affect group had nearly double the improvement in activity expenditure by one year: they were expending kilocalories at a rate equivalent to walking nearly 7.5 miles/week, compared to the control group who were expending kilocalories at a rate of about 4.1 miles/week.

Dr. Peterson cautions that a longer-term study would be needed to determine the impact of induction of Positive Affect on life expectancy, major complications and disability in older adults. Nevertheless, the effects on physical activity were so compelling that she and colleagues have further adapted the intervention to motivate other patient populations, including her group of older patients with a high burden of chronic disease. Every study participant will receive a FitBit®, a wireless device used to track daily exercise, and will be followed closely for a year. After developing a tailored exercise plan together, the patients and Dr. Peterson will track their progress and recalibrate the regimen if necessary. Her next step will be a larger randomized controlled trial to validate the intervention's usefulness as a new tool for healthcare providers to employ in older adults with high burdens of chronic disease.

"My own parents have chronic illness and I've worked in clinical research for many years," Dr. Peterson says, so she wanted to apply her experience, skills, and passion to help older adults navigate the trials she encountered with her family. "That's what the Beeson mission is all about—working together with other leaders in aging, leveraging our knowledge and collaborating, to improve the health of older adults."

Vivek Prabhakaran, MD, PhD

Assistant Professor of Neuroradiology, University of Wisconsin School of Medicine and Public Health

Mentor: Patrick Turski, MD, FACR

Stroke Plasticity



Stroke, characterized by a sharp reduction or interruption of the brain's blood supply, is one of the leading causes of death and disability in the United States. With about 800,000 strokes occurring annually, the population of survivors has swelled to an estimated 4 million. "That basically means that there are more people that need adequate rehabilitation so that they can be functionally better in being able to participate in real-world activities," says Vivek Prabhakaran, MD, PhD.

To help patients achieve the best post-stroke rehabilitation, however, researchers need a better understanding of how brain networks change and adapt to the injury, a phenomenon known as stroke plasticity. "The initial stroke can lead to network dysfunction," Dr. Prabhakaran says, "and then the question is what happens later on and how does the network reorganize and recover? And how can we shape the recovery process in a way that's adaptive towards function as well as suppress some of the maladaptive plasticity changes that may occur, which may actually be impairing functional recovery?"

Beyond conducting research into how doctors might encourage adaptive rewiring in the brain and discourage maladaptive changes, Dr. Prabhakaran's Beeson project is also aimed at understanding the critical time window for intervening and shaping the plasticity in a way that's helpful. Finally, he is developing methods to help predict which patients will recover more fully than others. For those likely to struggle with their recovery, for example, doctors might want to pursue more aggressive rehabilitation strategies.

Dr. Prabhakaran and colleagues are collecting data from up to 75 stroke patients and also collecting extensive neuropsychological datasets as well as utilizing advanced neuroimaging techniques to collect data of functional and structural assessments of each patient's brain. "We think these additional imaging measures have very important information that can be helpful in understanding their recovery, prognostics and the critical time window for intervention," he says.

The researchers start their assessments within a week of each patient's stroke and follow up at specific time intervals until a year after the initial brain injury. The extensive time frame can help them relate changes in the neuroimaging measures to changes in a patient's neuropsychological measures. From the emerging relationships, Dr. Prabhakaran may be able to determine the hallmarks of a good or bad recovery and use these patterns to better inform stroke rehabilitation strategies.

Immediately after a stroke, the "stunned brain" largely shuts down in the acute phase, before dramatically ramping up its activation of various networks in the subacute phase and then pruning some of the connections to remodel its networks during the chronic phase. "This is occurring over weeks to months, really, in terms of the whole shaping of brain plasticity and corresponding behavioral changes," he says.

Dr. Prabhakaran has long been interested in normal aging, cognition and the mechanisms that underlie changes in the brain's networks. "As I moved to my clinical years, I became more and more exposed to clinical patient populations who suffered a stroke. Stroke is very devastating and has an incredible morbidity and mortality associated with it," he says. He began asking some of the same questions about altered brain networks and cognition in stroke patients. Because of the definitive onset of a stroke injury with the sudden interruption of blood flow, he realized that he would be able to track the entire recovery process.

The Beeson award, he says, has been a "tremendous" asset in letting him pursue such an ambitious research agenda. The award has been an important stepping-stone to additional grants and awards that have allowed him to branch out by focusing on his own stroke rehabilitation technique.

The innovative method, called a brain-computer interface technique, gives patients immediate biofeedback of their own brain in action while they conduct a specific task, such as moving a hand. The technique, which Dr. Prabhakaran is refining in patient populations, links the brain's central activity with peripheral movement. "They're able to modulate the brain activity to improve their outcomes," he says. "So it basically harnesses brain plasticity for recovery."



2014

Kumar Dharmarajan, MD, MBA Yale University School of Medicine

Anne Hiniker, MD, PhD University of California, San Francisco

Jennifer Lai, MD, MBA University of California, San Francisco

Kasia Lipska, MD Yale University School of Medicine

Donovan Maust, MD University of Michigan

John Newman, MD, PhD University of California San Francisco

Kelly Trevino, MD Weill Cornell Medicine

Kathleen Unroe, MD Indiana University

2013

Marian E. Betz, MD, MPH University of Colorado Denver Anschutz Medical Campus

Constance H. Fung, MD, MSHS David Geffen School of Medicine at the University of California, Los Angeles

William Hu, MD, PhD Emory University School of Medicine

Daniel B. Kramer, MD Harvard Medical School/Hebrew Rehabilitation Center

Ozioma Okonkwo, PhD University of Wisconsin School of Medicine and Public Health

Janey Peterson, EdD, MS, RN Weill Cornell Medicine

Vivek Prabhakaran, MD, PhDUniversity of Wisconsin School of Medicine and Public Health

2012

S. Duke Han, PhD Rush University Medical Center

Amy S. Kelley, MD, MSHS Icahn School of Medicine at Mount Sinai

Geoffrey A. Kerchner, MD, PhD Genentech

Gerardo Moreno, MD, MSHS David Geffen School of Medicine at the University of California, Los Angeles

Alexander Panda, MD, PhD, MPH Tufts University School of Medicine

Steven J. Prior, PhD
University of Maryland School of Medicine

Alexander K. Smith, MD, MS, MPH University of California, San Francisco School of Medicine

2011

William J. Ehlenbach, MD, MSc University of Wisconsin School of Medicine and Public Health

Adit Ginde, MD, MPH University of Colorado Anschutz Medical Campus

Alison Huang, MD University of California, San Francisco School of Medicine

Richard D. King, MD, PhD University of Utah Health Sciences Center

Heidi Klepin, MD, MS Wake Forest University School of Medicine

Sei Lee, MD, MAS University of California, San Francisco School of Medicine

Dan Matlock, MD, MPH University of Colorado Anschutz Medical Campus

Keith Vossel, MD, MSc J. David Gladstone Institutes/University of California, San Francisco School of Medicine

2010

Jeffrey Caterino, MD, MPH Ohio State University College of Medicine

Anna Csiszár, MD, PhD University of Oklahoma Health Sciences Center

Leora I. Horwitz, MD, MHS New York University School of Medicine

Amy Kind, MD, PhD University of Wisconsin School of Medicine and Public Health

J. Michael McWilliams, MD, PhD Harvard Medical School/Brigham and Women's Hospital

Timothy M. Miller, MD, PhD Washington University School of Medicine in St. Louis Thomas Robinson, MD

University of Colorado Anschutz Medical Campus

Stephen M. Thielke, MD, MSPH, MA

University of Washington School of Medicine

2009

Cynthia Boyd, MD, MPH

Johns Hopkins University School of Medicine

Dena Dubal, MD, PhD

University of California, San Francisco School of Medicine

Chie Wei Fan, MD, RCPI

Trinity College Dublin, Ireland

Ronan H. Mullan, MBChB, PhD

Trinity College Dublin, Ireland

Christiane Reitz, MD, PhD

Columbia University College of Physicians and Surgeons

Mara A. Schonberg, MD, MPH

Harvard Medical School/Beth Israel Deaconess Medical Center

Dorry L. Segev, MD, PhD

Johns Hopkins University School of Medicine

Edmond H. Teng, MD, PhD

David Geffen School of Medicine at the

University of California, Los Angeles

Heidi L. Wald, MD, MSPH

University of Colorado Anschutz Medical Campus

Jonathan Wanagat, MD, PhD

David Geffen School of Medicine at the

University of California, Los Angeles

2008

Sarwat I. Chaudhry, MD

Yale School of Medicine

Stephanie Cosentino, PhD

Columbia University College of Physicians and Surgeons

XinQi Dong, MD, MPH

Rush University Medical Center

Susan E. Hardy, MD, PhD

Paul B. Rosenberg, MD

Johns Hopkins University School of Medicine

Joseph S. Ross, MD, MHS

Yale School of Medicine

Steven J. Russell, MD, PhD

Harvard Medical School/Massachusetts General Hospital

Diabetes Research Center

Arthur A. Simen, MD, PhD

Pfizer

Farzaneh A. Sorond, MD, PhD

Harvard Medical School/Brigham & Women's Hospital

Michael A. Steinman, MD

University of California, San Francisco School of Medicine

Stephen A. Todd, MD, MRCP

Altnagelvin Hospital, Londonderry, Northern Ireland

Douglas B. White, MD, MAS

University of Pittsburgh Medical Center

Heather E. Whitson, MD, MHS

Duke University Medical Center

2007

Randall J. Bateman, MD

Washington University School of Medicine in St. Louis

Julie Bynum, MD, MPH

The Geisel School of Medicine at Dartmouth

Sascha Dublin, MD, PhD

University of Washington/Group Health Research Institute

Roee Holtzer, PhD

Albert Einstein College of Medicine

Angela L. Jefferson, PhD

Vanderbilt University Medical Center

Kimberly S. Johnson, MD

Duke University Medical Center

Kejal Kantarci, MD, MS

Mayo Clinic College of Medicine, Rochester

Patricia M. Kearney, MRCPI, PhD, MPH

University College Cork, Ireland

Manjula Kurella Tamura, MD, MPH

VA Palo Alto Health Care System and

Stanford School of Medicine

Bernadette McGuinness, MD, PhD, MRCP

Queen's University, Belfast, Ireland

Nicolas Musi, MD

University of Texas Health Science Center at San Antonio

School of Medicine

Neil A. Segal, MD, MS

Kansas University Medical Center

Lihong Wang, MD, PhD

University of Connecticut Health Center

2006

Katrin F. Chua, MD, PhD

Stanford University School of Medicine

Margaret C. Fang, MD, MPH

University of California, San Francisco School of Medicine

Alex D. Federman, MD, MPH

Icahn School of Medicine at Mount Sinai

Emily V.A. Finlayson, MD, MS

University of California, San Francisco School of Medicine

Stacy M. Fischer, MD

University of Colorado Anschutz Medical Campus

Alfred L. Fisher, MD, PhD

University of Texas Health Science Center at San Antonio

Sean X. Leng, MD, PhD

Johns Hopkins University School of Medicine

Ann M. O'Hare, MD

University of Washington School of Medicine

Caterina Rosano, MD, MPH

University of Pittsburgh Graduate School of Public Health

Manish N. Shah, MD, MPH

University of Wisconsin School of Medicine and Public Health

Consuelo H. Wilkins, MD, MSCI

Vanderbilt University School of Medicine

2005

Liana G. Apostolova, MD, MSc

Indiana University School of Medicine

Malaz A. Boustani, MD, MPH

Indiana University School of Medicine

Jennifer S. Brach, PhD

University of Pittsburgh School of Health and

Rehabilitation Sciences

Arleen F. Brown, MD, PhD

David Geffen School of Medicine at the University of California, Los Angeles

Cynthia M. Carlsson, MD, MS

University of Wisconsin School of Medicine and Public Health

Daniel R. Goldstein, MD

Yale School of Medicine

Wendolyn S. Gozansky, MD, MPH

Kaiser Permanente Colorado

Leanne Groban, MD

Wake Forest University School of Medicine

Arti Hurria, MD


City of Hope

Pearl H. Seo, MD, MPH

Miller School of Medicine at University of Miami

Dellara F. Terry, MD, MPH

Dovetail Health



2004

Sandy Chang, MD, PhD Yale School of Medicine

Cathleen S. Colon-Emeric, MD

Duke University Medical Center

William Dale, MD, PhD

University of Chicago School of Medicine

Lee E. Goldstein, MD, PhD

Boston University School of Medicine, College of Engineering & Photonics Center

Cary P. Gross, MD

Yale School of Medicine

John J. Lehman, MD

Washington University School of Medicine in St. Louis

Andrew P. Lieberman, MD, PhD

University of Michigan Medical School

Atul Malhotra, MD

University of California, San Diego School of Medicine

Martin J. Sadowski, MD, PhD

New York University School of Medicine

Catherine A. Sarkisian, MD, MSPH

David Geffen School of Medicine at the

University of California, Los Angeles

Clemens R. Scherzer, MD

Harvard Medical School/Brigham and Women's Hospital

Lisa C. Silbert, MD, MCR

Oregon Health and Science University

Joe Verghese, MD

Albert Einstein College of Medicine

2003

Meredith Hawkins, MD

Albert Einstein College of Medicine

Michael C. Irizarry, MD, MPH

Kenneth Langa, MD, PhD

University of Michigan Health System

Sarah H. Lisanby, MD

National Institute of Mental Health/National Institutes of Health

Jack M. Parent, MD

University of Michigan Health System

Henry L. Paulson, MD, PhD

University of Michigan Health System

Elizabeth A. Phelan, MD, MS

University of Washington School of Public Health

Wendy S. Post, MD, MS

Johns Hopkins University School of Medicine

Norman E. Sharpless, MD

University of North Carolina at Chapel Hill School of Medicine

Michael G. Shlipak, MD, MPH

University of California, San Francisco School of Medicine

Reisa A. Sperling, MD, MMSc

Harvard Medical School/Brigham and Women's Hospital/ Massachusetts General Hospital

2002

David J. Casarett, MD

University of Pennsylvania, Perelman School of Medicine

James E. Galvin, MD, MPH

Florida Atlantic University

F. Brad Johnson, MD, PhD

University of Pennsylvania, Perelman School of Medicine

Albert La Spada, MD, PhD, FACMG

University of California, San Diego School of Medicine

Michael T. Lin, MD

Weill Cornell Medicine

Robert A. Marciniak, MD, PhD

University of Texas Health Science Center at San Antonio

Laura E. Niklason, MD, PhD

Yale School of Medicine

Michael A. Schwarzschild, MD, PhD

Harvard Medical School/Massachusetts General Hospital

Jürgen Unützer, MD, MPH, MA

University of Washington Medical Center

2001

Asa Abeliovich, MD, PhD

Columbia University College of Physicians and Surgeons

Katrin Andreasson, MD

Stanford University School of Medicine

Eric A. Coleman, MD, MPH

University of Colorado Anschutz Medical Campus

Jay M. Edelberg, MD, PhD

Sanofi

E. Wesley Ely, MD, MPH, FCCP

Vanderbilt University School of Medicine/VA-GRECC

Roger J. Hajjar, MD

Icahn School of Medicine at Mount Sinai

James A. Mastrianni, MD, PhD

University of Chicago Pritzker School of Medicine

Michael C. Naski, MD, PhD

Mercy Health

M. Carrington Reid, MD, PhD

Weill Cornell Medicine

Mary Whooley, MD

University of California, San Francisco School of Medicine

Kristine Yaffe, MD

University of California, San Francisco School of Medicine

2000

Brock Beamer, MD

University of Maryland, Baltimore School of Medicine

Gunnar K. Gouras, MD

Lund University, Sweden

Mary Beth Hamel, MD, MPH

Harvard Medical School/Beth Israel Deaconess Medical Center

Joshua M. Hare, MD

Miller School of Medicine at University of Miami

Fuki M. Hisama, MD

University of Washington School of Medicine

Jason Karlawish, MD

University of Pennsylvania, Perelman School of Medicine

Jean S. Kutner, MD, MSPH

University of Colorado School of Medicine

Brett Lauring, MD, PhD

Merck Research Labs

Frank S. Lee, MD, PhD

University of Pennsylvania, Perelman School of Medicine

R. Sean Morrison, MD

Icahn School of Medicine at Mount Sinai

Scott A. Small, MD

Columbia University College of Physicians and Surgeons

1999

Kenneth E. Covinsky, MD, MPH

University of California, San Francisco School of Medicine

Matthew P. Frosch, MD, PhD

Harvard Medical School/Massachusetts General Hospital

Daniel T. Laskowitz, MD

Duke University Medical Center

Dale Leitman, MD, PhD

University of California, Berkeley

Richard Z. Lin, MD

Stony Brook University School of Medicine

David R. Lynch, MD, PhD

University of Pennsylvania, Perelman School of Medicine

Edward R. Marcantonio, MD, SM

Harvard Medical School/Beth Israel Deaconess Medical Center

Mitchell S. Nobler, MD

New York Medical College

Anne Louise Oaklander, MD, PhD

Harvard Medical School/Massachusetts General Hospital

Thomas A. Rando, MD, PhD

Stanford University School of Medicine

1998

Helene Benveniste, MD, PhD Stony Brook University Medical Center

Laura L. Dugan, MD Vanderbilt University School of Medicine

Terri R. Fried, MD Yale School of Medicine

Anne M. Kenny, MD University of Connecticut Health Center

Alison A. Moore, MD, MPH David Geffen School of Medicine at the University of California, Los Angeles

Thomas T. Perls, MD, MPH Boston University School of Medicine

Eric D. Peterson, MD, MPHDuke University Medical Center

R. Scott Turner, MD, PhD Georgetown University Medical Center

Jeremy D. Walston, MD Johns Hopkins University School of Medicine

Raymond L. Yung, MB, ChB University of Michigan Medical School

1997

Nir Barzilai, MD Albert Einstein College of Medicine

Michele F. Bellantoni, MD Johns Hopkins University School of Medicine

James R. Burke, MD, PhD Duke University Medical Center

Mark D'Esposito, MD University of California, Berkeley

Thomas M. Gill, MD Yale School of Medicine

Bernard F. Godley, MD, PhD, MBA The University of Texas Medical Branch

Todd E. Golde, MD, PhD University of Florida College of Medicine

Helen Hoenig, MD, MPH Duke University Medical Center

Elan D. Louis, MD, MSc Columbia University College of Physicians and Surgeons

Charles A. Thornton, MD University of Rochester School of Medicine and Dentistry

1996

Christopher M. Callahan, MD Indiana University School of Medicine

Robert W. Doms, MD, PhD University of Pennsylvania, Perelman School of Medicine

P. Murali Doraiswamy, MBBS Duke University Medical Center

Harlan M. Krumholz, MD Yale School of Medicine

Makau Lee, MD, PhD Baptist Health Systems

Richard F. Loeser, Jr., MD University of North Carolina School of Medicine

Karen M. Prestwood, MD Masonicare Health Center

May J. Reed, MD University of Washington School of Medicine

R. Glenn Smith, MD, PhD University of Texas Medical Branch

1995

Ashley I. Bush, MD, PhD University of Melbourne, Victoria, Australia

Ted M. Dawson, MD, PhD Johns Hopkins University School of Medicine

David M. Holtzman, MD Washington University School of Medicine in St. Louis

Edward H. Koo, MD University of California, San Diego School of Medicine

Mark Lachs, MD, MPH Weill Cornell Medicine

Frank M. Longo, MD, PhD Stanford University School of Medicine

Richard A. Marottoli, MD, MPH Yale School of Medicine

Lina M. Obeid, MD Stony Brook School of Medicine

Peter Reaven, MD University of Arizona School of Medicine, Phoenix

Alan R. Shuldiner, MD University of Maryland, Baltimore School of Medicine

Sponsored by

National Institute on Aging

National Institute of Neurological Disorders and Stroke

The Atlantic Philanthropies

The John A. Hartford Foundation

Administered by

National Institute on Aging

American Federation for Aging Research

The American Federation for Aging Research (AFAR) is a nonprofit organization whose mission is to support biomedical research on aging. It is devoted to creating the knowledge that all of us need to live healthy, productive, and independent lives. Since 1981, AFAR has awarded more than \$150 million to over 3,000 talented scientists as part of its broad-based series of grant programs. Its work has led to significant advances in our understanding of aging processes, age-related diseases, and healthy aging practices. Learn more at www.afar.org.

The National Institute on Aging (NIA), one of the 27 institutes and centers of the National Institutes of Health, leads a broad scientific effort to understand the nature of aging and to extend the healthy, active years of life. In 1974, Congress granted authority to form the National Institute on Aging to provide leadership in aging research, training, health information dissemination, and other programs relevant to aging and older people. The NIA's mission is to support and conduct genetic, biological, clinical, behavioral, social, and economic research related to the aging process, diseases and conditions associated with aging, and other special problems and needs of older Americans, foster the development of scientists in aging and communicate information about aging and advances in research on aging to the scientific community, health care providers, and the public. Learn more at www.nia.nih.gov.

Credits

Writing: Bryn Nelson | Design: John Chaich

We would like to thank the Beeson Scholars for reviewing this report for scientific accuracy.

